<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    10796511
   </pmid>
   <datecreated>
    <year>
     2000
    </year>
    <month>
     07
    </month>
    <day>
     06
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2000
    </year>
    <month>
     07
    </month>
    <day>
     06
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2007
    </year>
    <month>
     10
    </month>
    <day>
     18
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Electronic">
      1469-493X
     </issn>
     <journalissue citedmedium="Internet">
      <issue>
       2
      </issue>
      <pubdate>
       <year>
        2000
       </year>
      </pubdate>
     </journalissue>
     <title>
      Cochrane database of systematic reviews (Online)
     </title>
     <isoabbreviation>
      Cochrane Database Syst Rev
     </isoabbreviation>
    </journal>
    <articletitle>
     Drugs for treating giardiasis.
    </articletitle>
    <pagination>
     <medlinepgn>
      CD000217
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
      There can be a high rate of recurrence of disease after initial drug treatment for giardiasis. These drugs also have a range of adverse effects.
     </abstracttext>
     <abstracttext label="OBJECTIVES" nlmcategory="OBJECTIVE">
      The objective of this review was to assess the effects of drug treatments for giardiasis.
     </abstracttext>
     <abstracttext label="SEARCH STRATEGY" nlmcategory="METHODS">
      We searched the Cochrane Infectious Diseases Group trials register, the Cochrane Controlled Trials Register, Medline and Embase, Current Contents, reference lists of articles.
     </abstracttext>
     <abstracttext label="SELECTION CRITERIA" nlmcategory="METHODS">
      Randomised and quasi-randomised trials of drug therapy for giardiasis compared with placebo or another drug.
     </abstracttext>
     <abstracttext label="DATA COLLECTION AND ANALYSIS" nlmcategory="METHODS">
      Two reviewers independently assessed trial quality and extracted data.
     </abstracttext>
     <abstracttext label="MAIN RESULTS" nlmcategory="RESULTS">
      Thirty-four trials were included. Only one trial was without serious methodological flaws. Compared with placebo, drug treatment was associated with an improved cure rate (odds ratio 11.5, 95% confidence interval 2.3 to 58). Metronidazole treatment longer than three days had a better parasitological cure rate than other long treatment courses (odds ratio 2.4, 95% confidence interval 1.3 to 4.4), but there was significant heterogeneity between the trials. Single dose therapy appeared equally effective as longer treatment courses (odds ratio 0.33, 95% confidence interval 0.08 to 1.34). Within the single dose regimens, tinidazole had a comparable parasitological cure rate to other short therapies (odds ratio 3.4, 95% confidence interval 0.95 to 12), but had a higher clinical cure rate (odds ratio 5.3, 95% 2.7-10.7).
     </abstracttext>
     <abstracttext label="REVIEWER'S CONCLUSIONS" nlmcategory="CONCLUSIONS">
      A single dose of tinidazole appears to give the highest clinical cure rate for giardiasis with relatively few adverse effects.
     </abstracttext>
    </abstract>
    <affiliation>
     Fluitekruid 13, 1441 XP Purmerend, Amsterdam, Netherlands. jzaat@knmg.nl
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Zaat
      </lastname>
      <forename>
       J O
      </forename>
      <initials>
       JO
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Mank
      </lastname>
      <forename>
       T h
      </forename>
      <initials>
       T
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Assendelft
      </lastname>
      <forename>
       W J
      </forename>
      <initials>
       WJ
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Review
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     ENGLAND
    </country>
    <medlineta>
     Cochrane Database Syst Rev
    </medlineta>
    <nlmuniqueid>
     100909747
    </nlmuniqueid>
    <issnlinking>
     1361-6137
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Antiprotozoal Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      19387-91-8
     </registrynumber>
     <nameofsubstance>
      Tinidazole
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      443-48-1
     </registrynumber>
     <nameofsubstance>
      Metronidazole
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      67-45-8
     </registrynumber>
     <nameofsubstance>
      Furazolidone
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="UpdateIn">
     <refsource>
      Cochrane Database Syst Rev. 2007;(2):CD000217
     </refsource>
     <pmid version="1">
      17636622
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Antiprotozoal Agents
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Furazolidone
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Giardiasis
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Metronidazole
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Tinidazole
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
   </meshheadinglist>
   <numberofreferences>
    34
   </numberofreferences>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2000
     </year>
     <month>
      5
     </month>
     <day>
      5
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2000
     </year>
     <month>
      7
     </month>
     <day>
      8
     </day>
     <hour>
      11
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2000
     </year>
     <month>
      5
     </month>
     <day>
      5
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     10796511
    </articleid>
    <articleid idtype="pii">
     CD000217
    </articleid>
    <articleid idtype="doi">
     10.1002/14651858.CD000217
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

